"sample_molecule_ch1","sample_molecule_ch2","sample_source_name_ch1","sample_status","sample_library_selection","sample_library_source","sample_extract_protocol_ch1","sample_extract_protocol_ch2","sample_label_protocol_ch1","sample_source_name_ch2","sample_library_strategy","sample_characteristics_ch2","sample_label_protocol_ch2","sample_label_protocol","sample_series_id","sample_data_processing","sample_description","sample_characteristics_ch1","sample_organism_ch1","tissue","sample_type","sample_title","sample_name","sample_hyb_protocol","sample_label_ch2","disease_state","ethnicity","time_point","tmprss2","treatment","cancer_status","tissuer_type","tumor_type","age","gleason_score","pathologic_tumor_stage","gleason_grade","t-stage","margin_status","preop_psa","bcr","bcr_free_time"
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_001","congenital_nevi_001","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_002","congenital_nevi_002","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_003","congenital_nevi_003","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_004","congenital_nevi_004","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_005","congenital_nevi_005","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_006","congenital_nevi_006","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_007","congenital_nevi_007","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_008","congenital_nevi_008","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Congenital Nevi","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): NA(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): NA(follow-up time (months): NA","Homo sapiens",NA,"RNA","Congenital Nevi_009","congenital_nevi_009","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.8(time to 1st recurrence (days): 665(time to 1st recurrence (months): 22(time to b-met (days): NA(follow-up time (days): 6159(follow-up time (months): 202","Homo sapiens",NA,"RNA","Primary Melanoma_010","primary_melanoma_010","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,64,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.4(time to 1st recurrence (days): 3829(time to 1st recurrence (months): 125(time to b-met (days): 4851(follow-up time (days): 5092(follow-up time (months): 167","Homo sapiens",NA,"RNA","Primary Melanoma_011","primary_melanoma_011","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,51,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.75(time to 1st recurrence (days): 472(time to 1st recurrence (months): 16(time to b-met (days): 1735(follow-up time (days): 1910(follow-up time (months): 62","Homo sapiens",NA,"RNA","Primary Melanoma_012","primary_melanoma_012","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,69,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.7(time to 1st recurrence (days): 346(time to 1st recurrence (months): 12(time to b-met (days): NA(follow-up time (days): 3328(follow-up time (months): 109","Homo sapiens",NA,"RNA","Primary Melanoma_013","primary_melanoma_013","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,86,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.88(time to 1st recurrence (days): 250(time to 1st recurrence (months): 8(time to b-met (days): NA(follow-up time (days): 3266(follow-up time (months): 107","Homo sapiens",NA,"RNA","Primary Melanoma_014","primary_melanoma_014","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,82,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.6(time to 1st recurrence (days): 1218(time to 1st recurrence (months): 40(time to b-met (days): NA(follow-up time (days): 7033(follow-up time (months): 231","Homo sapiens",NA,"RNA","Primary Melanoma_015","primary_melanoma_015","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,66,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): 580(time to 1st recurrence (months): 19(time to b-met (days): 688(follow-up time (days): 1025(follow-up time (months): 33","Homo sapiens",NA,"RNA","Primary Melanoma_016","primary_melanoma_016","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.7(time to 1st recurrence (days): 455(time to 1st recurrence (months): 15(time to b-met (days): 455(follow-up time (days): 620(follow-up time (months): 20","Homo sapiens",NA,"RNA","Primary Melanoma_017","primary_melanoma_017","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,76,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.3(time to 1st recurrence (days): 1981(time to 1st recurrence (months): 65(time to b-met (days): NA(follow-up time (days): 3031(follow-up time (months): 99","Homo sapiens",NA,"RNA","Primary Melanoma_018","primary_melanoma_018","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,67,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.2(time to 1st recurrence (days): 1414(time to 1st recurrence (months): 47(time to b-met (days): 2281(follow-up time (days): 2508(follow-up time (months): 82","Homo sapiens",NA,"RNA","Primary Melanoma_019","primary_melanoma_019","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.3(time to 1st recurrence (days): 1149(time to 1st recurrence (months): 37(time to b-met (days): NA(follow-up time (days): 3499(follow-up time (months): 114","Homo sapiens",NA,"RNA","Primary Melanoma_020","primary_melanoma_020","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,63,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): 679(time to 1st recurrence (months): 23(time to b-met (days): NA(follow-up time (days): 1067(follow-up time (months): 35","Homo sapiens",NA,"RNA","Primary Melanoma_021","primary_melanoma_021","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,39,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5(time to 1st recurrence (days): 683(time to 1st recurrence (months): 23(time to b-met (days): 683(follow-up time (days): 896(follow-up time (months): 29","Homo sapiens",NA,"RNA","Primary Melanoma_022","primary_melanoma_022","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 7(time to 1st recurrence (days): 364(time to 1st recurrence (months): 12(time to b-met (days): 544(follow-up time (days): 592(follow-up time (months): 19","Homo sapiens",NA,"RNA","Primary Melanoma_023","primary_melanoma_023","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 10.1(time to 1st recurrence (days): 412(time to 1st recurrence (months): 14(time to b-met (days): 788(follow-up time (days): 810(follow-up time (months): 26","Homo sapiens",NA,"RNA","Primary Melanoma_024","primary_melanoma_024","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,77,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 6(time to 1st recurrence (days): 345(time to 1st recurrence (months): 11(time to b-met (days): 345(follow-up time (days): 548(follow-up time (months): 18","Homo sapiens",NA,"RNA","Primary Melanoma_025","primary_melanoma_025","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,44,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 7(time to 1st recurrence (days): 779(time to 1st recurrence (months): 26(time to b-met (days): NA(follow-up time (days): 2352(follow-up time (months): 77","Homo sapiens",NA,"RNA","Primary Melanoma_026","primary_melanoma_026","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,69,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5.5(time to 1st recurrence (days): 3614(time to 1st recurrence (months): 119(time to b-met (days): 5996(follow-up time (days): 6038(follow-up time (months): 198","Homo sapiens",NA,"RNA","Primary Melanoma_027","primary_melanoma_027","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5.5(time to 1st recurrence (days): 1132(time to 1st recurrence (months): 38(time to b-met (days): 1356(follow-up time (days): 1387(follow-up time (months): 45","Homo sapiens",NA,"RNA","Primary Melanoma_028","primary_melanoma_028","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.2(time to 1st recurrence (days): 167(time to 1st recurrence (months): 5(time to b-met (days): NA(follow-up time (days): 318(follow-up time (months): 10","Homo sapiens",NA,"RNA","Primary Melanoma_029","primary_melanoma_029","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.92(time to 1st recurrence (days): 862(time to 1st recurrence (months): 28(time to b-met (days): 862(follow-up time (days): 4612(follow-up time (months): 151","Homo sapiens",NA,"RNA","Primary Melanoma_030","primary_melanoma_030","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,53,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.3(time to 1st recurrence (days): 352(time to 1st recurrence (months): 12(time to b-met (days): 433(follow-up time (days): 484(follow-up time (months): 15","Homo sapiens",NA,"RNA","Primary Melanoma_031","primary_melanoma_031","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,57,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.2(time to 1st recurrence (days): 1343(time to 1st recurrence (months): 44(time to b-met (days): 1343(follow-up time (days): 1466(follow-up time (months): 48","Homo sapiens",NA,"RNA","Primary Melanoma_032","primary_melanoma_032","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,45,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.2(time to 1st recurrence (days): 331(time to 1st recurrence (months): 11(time to b-met (days): 553(follow-up time (days): 642(follow-up time (months): 21","Homo sapiens",NA,"RNA","Primary Melanoma_033","primary_melanoma_033","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 6.6(time to 1st recurrence (days): 5444(time to 1st recurrence (months): 179(time to b-met (days): NA(follow-up time (days): 5682(follow-up time (months): 186","Homo sapiens",NA,"RNA","Primary Melanoma_034","primary_melanoma_034","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 22(time to 1st recurrence (days): 143(time to 1st recurrence (months): 5(time to b-met (days): 2025(follow-up time (days): 4721(follow-up time (months): 155","Homo sapiens",NA,"RNA","Primary Melanoma_035","primary_melanoma_035","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,41,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): 888(time to 1st recurrence (months): 29(time to b-met (days): 1686(follow-up time (days): 1783(follow-up time (months): 58","Homo sapiens",NA,"RNA","Primary Melanoma_036","primary_melanoma_036","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,34,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 7(time to 1st recurrence (days): 461(time to 1st recurrence (months): 15(time to b-met (days): NA(follow-up time (days): 845(follow-up time (months): 27","Homo sapiens",NA,"RNA","Primary Melanoma_037","primary_melanoma_037","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,77,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): 218(time to 1st recurrence (months): 8(time to b-met (days): 693(follow-up time (days): 729(follow-up time (months): 23","Homo sapiens",NA,"RNA","Primary Melanoma_038","primary_melanoma_038","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.7(time to 1st recurrence (days): 186(time to 1st recurrence (months): 6(time to b-met (days): NA(follow-up time (days): 995(follow-up time (months): 32","Homo sapiens",NA,"RNA","Primary Melanoma_039","primary_melanoma_039","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,48,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.2(time to 1st recurrence (days): 545(time to 1st recurrence (months): 18(time to b-met (days): 622(follow-up time (days): 655(follow-up time (months): 21","Homo sapiens",NA,"RNA","Primary Melanoma_040","primary_melanoma_040","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,83,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 30(time to 1st recurrence (days): 1164(time to 1st recurrence (months): 38(time to b-met (days): 1164(follow-up time (days): 1290(follow-up time (months): 42","Homo sapiens",NA,"RNA","Primary Melanoma_041","primary_melanoma_041","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,51,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1285(follow-up time (months): 42","Homo sapiens",NA,"RNA","Primary Melanoma_042","primary_melanoma_042","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,59,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3046(follow-up time (months): 100","Homo sapiens",NA,"RNA","Primary Melanoma_043","primary_melanoma_043","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.15(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1132(follow-up time (months): 37","Homo sapiens",NA,"RNA","Primary Melanoma_044","primary_melanoma_044","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 0.95(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2730(follow-up time (months): 89","Homo sapiens",NA,"RNA","Primary Melanoma_045","primary_melanoma_045","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,56,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.7(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3187(follow-up time (months): 104","Homo sapiens",NA,"RNA","Primary Melanoma_046","primary_melanoma_046","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,58,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.56(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3147(follow-up time (months): 103","Homo sapiens",NA,"RNA","Primary Melanoma_047","primary_melanoma_047","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.4(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2737(follow-up time (months): 89","Homo sapiens",NA,"RNA","Primary Melanoma_048","primary_melanoma_048","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,33,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3534(follow-up time (months): 116","Homo sapiens",NA,"RNA","Primary Melanoma_049","primary_melanoma_049","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,69,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.75(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2719(follow-up time (months): 89","Homo sapiens",NA,"RNA","Primary Melanoma_050","primary_melanoma_050","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,27,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.55(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2128(follow-up time (months): 69","Homo sapiens",NA,"RNA","Primary Melanoma_051","primary_melanoma_051","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,59,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 0.9(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3255(follow-up time (months): 106","Homo sapiens",NA,"RNA","Primary Melanoma_052","primary_melanoma_052","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.32(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1715(follow-up time (months): 56","Homo sapiens",NA,"RNA","Primary Melanoma_053","primary_melanoma_053","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,47,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2368(follow-up time (months): 77","Homo sapiens",NA,"RNA","Primary Melanoma_054","primary_melanoma_054","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,37,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.9(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3717(follow-up time (months): 122","Homo sapiens",NA,"RNA","Primary Melanoma_055","primary_melanoma_055","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.3(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3230(follow-up time (months): 106","Homo sapiens",NA,"RNA","Primary Melanoma_056","primary_melanoma_056","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,71,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.53(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3227(follow-up time (months): 106","Homo sapiens",NA,"RNA","Primary Melanoma_057","primary_melanoma_057","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,52,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.9(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2296(follow-up time (months): 75","Homo sapiens",NA,"RNA","Primary Melanoma_058","primary_melanoma_058","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.7(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3341(follow-up time (months): 109","Homo sapiens",NA,"RNA","Primary Melanoma_059","primary_melanoma_059","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1786(follow-up time (months): 58","Homo sapiens",NA,"RNA","Primary Melanoma_060","primary_melanoma_060","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.8(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2686(follow-up time (months): 88","Homo sapiens",NA,"RNA","Primary Melanoma_061","primary_melanoma_061","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,42,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2790(follow-up time (months): 91","Homo sapiens",NA,"RNA","Primary Melanoma_062","primary_melanoma_062","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,58,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.1(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2213(follow-up time (months): 72","Homo sapiens",NA,"RNA","Primary Melanoma_063","primary_melanoma_063","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,68,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.01(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2449(follow-up time (months): 80","Homo sapiens",NA,"RNA","Primary Melanoma_064","primary_melanoma_064","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,67,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.8(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1921(follow-up time (months): 63","Homo sapiens",NA,"RNA","Primary Melanoma_065","primary_melanoma_065","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,45,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.8(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2594(follow-up time (months): 85","Homo sapiens",NA,"RNA","Primary Melanoma_066","primary_melanoma_066","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,84,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2817(follow-up time (months): 92","Homo sapiens",NA,"RNA","Primary Melanoma_067","primary_melanoma_067","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,38,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 6(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3271(follow-up time (months): 107","Homo sapiens",NA,"RNA","Primary Melanoma_068","primary_melanoma_068","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,86,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.4(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3423(follow-up time (months): 112","Homo sapiens",NA,"RNA","Primary Melanoma_069","primary_melanoma_069","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.3(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3231(follow-up time (months): 106","Homo sapiens",NA,"RNA","Primary Melanoma_070","primary_melanoma_070","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,53,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1601(follow-up time (months): 52","Homo sapiens",NA,"RNA","Primary Melanoma_071","primary_melanoma_071","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,84,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): 1879(time to 1st recurrence (months): 61(time to b-met (days): NA(follow-up time (days): 2126(follow-up time (months): 69","Homo sapiens",NA,"RNA","Primary Melanoma_072","primary_melanoma_072","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2128(follow-up time (months): 69","Homo sapiens",NA,"RNA","Primary Melanoma_073","primary_melanoma_073","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 8(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2222(follow-up time (months): 72","Homo sapiens",NA,"RNA","Primary Melanoma_074","primary_melanoma_074","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3026(follow-up time (months): 99","Homo sapiens",NA,"RNA","Primary Melanoma_075","primary_melanoma_075","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,67,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.75(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2870(follow-up time (months): 94","Homo sapiens",NA,"RNA","Primary Melanoma_076","primary_melanoma_076","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,47,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.8(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2030(follow-up time (months): 66","Homo sapiens",NA,"RNA","Primary Melanoma_077","primary_melanoma_077","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,83,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 11(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2102(follow-up time (months): 69","Homo sapiens",NA,"RNA","Primary Melanoma_078","primary_melanoma_078","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,69,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 9(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1368(follow-up time (months): 44","Homo sapiens",NA,"RNA","Primary Melanoma_079","primary_melanoma_079","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,70,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 8(time to 1st recurrence (days): 1192(time to 1st recurrence (months): 58(time to b-met (days): NA(follow-up time (days): 1209(follow-up time (months): 39","Homo sapiens",NA,"RNA","Primary Melanoma_080","primary_melanoma_080","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,70,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.95(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3625(follow-up time (months): 119","Homo sapiens",NA,"RNA","Primary Melanoma_081","primary_melanoma_081","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,55,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.7(time to 1st recurrence (days): 1583(time to 1st recurrence (months): 52(time to b-met (days): NA(follow-up time (days): 2100(follow-up time (months): 68","Homo sapiens",NA,"RNA","Primary Melanoma_082","primary_melanoma_082","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,66,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 12(time to 1st recurrence (days): 642(time to 1st recurrence (months): 21(time to b-met (days): NA(follow-up time (days): 1105(follow-up time (months): 36","Homo sapiens",NA,"RNA","Primary Melanoma_083","primary_melanoma_083","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,66,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.91(time to 1st recurrence (days): 657(time to 1st recurrence (months): 22(time to b-met (days): NA(follow-up time (days): 1040(follow-up time (months): 34","Homo sapiens",NA,"RNA","Primary Melanoma_084","primary_melanoma_084","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,64,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.1(time to 1st recurrence (days): 2591(time to 1st recurrence (months): 85(time to b-met (days): NA(follow-up time (days): 5666(follow-up time (months): 186","Homo sapiens",NA,"RNA","Primary Melanoma_085","primary_melanoma_085","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 0.85(time to 1st recurrence (days): 287(time to 1st recurrence (months): 10(time to b-met (days): 510(follow-up time (days): 599(follow-up time (months): 19","Homo sapiens",NA,"RNA","Primary Melanoma_086","primary_melanoma_086","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,51,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.37(time to 1st recurrence (days): 123(time to 1st recurrence (months): 3(time to b-met (days): 398(follow-up time (days): 555(follow-up time (months): 18","Homo sapiens",NA,"RNA","Primary Melanoma_087","primary_melanoma_087","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,34,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.3(time to 1st recurrence (days): 403(time to 1st recurrence (months): 13(time to b-met (days): 763(follow-up time (days): 985(follow-up time (months): 32","Homo sapiens",NA,"RNA","Primary Melanoma_088","primary_melanoma_088","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,85,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.7(time to 1st recurrence (days): 635(time to 1st recurrence (months): 21(time to b-met (days): 1180(follow-up time (days): 1400(follow-up time (months): 46","Homo sapiens",NA,"RNA","Primary Melanoma_089","primary_melanoma_089","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,61,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.2(time to 1st recurrence (days): 2394(time to 1st recurrence (months): 79(time to b-met (days): NA(follow-up time (days): 6546(follow-up time (months): 215","Homo sapiens",NA,"RNA","Primary Melanoma_090","primary_melanoma_090","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,48,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.5(time to 1st recurrence (days): 307(time to 1st recurrence (months): 10(time to b-met (days): 738(follow-up time (days): 952(follow-up time (months): 31","Homo sapiens",NA,"RNA","Primary Melanoma_091","primary_melanoma_091","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.5(time to 1st recurrence (days): 366(time to 1st recurrence (months): 12(time to b-met (days): NA(follow-up time (days): 4818(follow-up time (months): 158","Homo sapiens",NA,"RNA","Primary Melanoma_092","primary_melanoma_092","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): 498(time to 1st recurrence (months): 16(time to b-met (days): NA(follow-up time (days): 3019(follow-up time (months): 99","Homo sapiens",NA,"RNA","Primary Melanoma_093","primary_melanoma_093","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 10(time to 1st recurrence (days): 167(time to 1st recurrence (months): 5(time to b-met (days): NA(follow-up time (days): 375(follow-up time (months): 12","Homo sapiens",NA,"RNA","Primary Melanoma_094","primary_melanoma_094","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,47,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 8(time to 1st recurrence (days): 232(time to 1st recurrence (months): 8(time to b-met (days): 595(follow-up time (days): 695(follow-up time (months): 22","Homo sapiens",NA,"RNA","Primary Melanoma_095","primary_melanoma_095","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,74,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.6(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2815(follow-up time (months): 92","Homo sapiens",NA,"RNA","Primary Melanoma_096","primary_melanoma_096","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,35,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.1(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3234(follow-up time (months): 106","Homo sapiens",NA,"RNA","Primary Melanoma_097","primary_melanoma_097","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2272(follow-up time (months): 74","Homo sapiens",NA,"RNA","Primary Melanoma_098","primary_melanoma_098","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.75(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 959(follow-up time (months): 31","Homo sapiens",NA,"RNA","Primary Melanoma_099","primary_melanoma_099","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,69,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.1(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3126(follow-up time (months): 102","Homo sapiens",NA,"RNA","Primary Melanoma_100","primary_melanoma_100","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,81,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array power labelling kit (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62370, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1413(follow-up time (months): 46","Homo sapiens",NA,"RNA","Primary Melanoma_101","primary_melanoma_101","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides were scanned and stored  ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 10(time to 1st recurrence (days): 617(time to 1st recurrence (months): 20(time to b-met (days): 1088(follow-up time (days): 1094(follow-up time (months): 35","Homo sapiens",NA,"RNA","Primary Melanoma_001","primary_melanoma_001","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,81,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.7(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3860(follow-up time (months): 126","Homo sapiens",NA,"RNA","Primary Melanoma_002","primary_melanoma_002","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.6(time to 1st recurrence (days): 234(time to 1st recurrence (months): 8(time to b-met (days): NA(follow-up time (days): 525(follow-up time (months): 17","Homo sapiens",NA,"RNA","Primary Melanoma_003","primary_melanoma_003","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,87,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.06(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3092(follow-up time (months): 101","Homo sapiens",NA,"RNA","Primary Melanoma_004","primary_melanoma_004","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,35,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 10.75(time to 1st recurrence (days): 258(time to 1st recurrence (months): 9(time to b-met (days): NA(follow-up time (days): 896(follow-up time (months): 29","Homo sapiens",NA,"RNA","Primary Melanoma_005","primary_melanoma_005","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,76,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 30(time to 1st recurrence (days): 1093(time to 1st recurrence (months): 36(time to b-met (days): NA(follow-up time (days): 1356(follow-up time (months): 44","Homo sapiens",NA,"RNA","Primary Melanoma_006","primary_melanoma_006","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,77,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.6(time to 1st recurrence (days): 1011(time to 1st recurrence (months): 33(time to b-met (days): 1011(follow-up time (days): 1030(follow-up time (months): 33","Homo sapiens",NA,"RNA","Primary Melanoma_007","primary_melanoma_007","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,73,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5.1(time to 1st recurrence (days): 385(time to 1st recurrence (months): 13(time to b-met (days): NA(follow-up time (days): 601(follow-up time (months): 19","Homo sapiens",NA,"RNA","Primary Melanoma_008","primary_melanoma_008","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3793(follow-up time (months): 124","Homo sapiens",NA,"RNA","Primary Melanoma_009","primary_melanoma_009","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,61,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 10(time to 1st recurrence (days): 573(time to 1st recurrence (months): 18(time to b-met (days): 1734(follow-up time (days): 1953(follow-up time (months): 64","Homo sapiens",NA,"RNA","Primary Melanoma_010","primary_melanoma_010","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,57,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 12(time to 1st recurrence (days): 642(time to 1st recurrence (months): 21(time to b-met (days): NA(follow-up time (days): 1105(follow-up time (months): 36","Homo sapiens",NA,"RNA","Primary Melanoma_011","primary_melanoma_011","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,66,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.1(time to 1st recurrence (days): 2143(time to 1st recurrence (months): 71(time to b-met (days): NA(follow-up time (days): 2284(follow-up time (months): 75","Homo sapiens",NA,"RNA","Primary Melanoma_012","primary_melanoma_012","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,70,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.62(time to 1st recurrence (days): 316(time to 1st recurrence (months): 10(time to b-met (days): NA(follow-up time (days): 1096(follow-up time (months): 36","Homo sapiens",NA,"RNA","Primary Melanoma_013","primary_melanoma_013","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,51,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 10(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 378(follow-up time (months): 12","Homo sapiens",NA,"RNA","Primary Melanoma_014","primary_melanoma_014","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,83,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5(time to 1st recurrence (days): 830(time to 1st recurrence (months): 27(time to b-met (days): 1085(follow-up time (days): 1196(follow-up time (months): 39","Homo sapiens",NA,"RNA","Primary Melanoma_015","primary_melanoma_015","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,77,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.65(time to 1st recurrence (days): 167(time to 1st recurrence (months): 6(time to b-met (days): 403(follow-up time (days): 471(follow-up time (months): 15","Homo sapiens",NA,"RNA","Primary Melanoma_016","primary_melanoma_016","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,81,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.3(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3202(follow-up time (months): 105","Homo sapiens",NA,"RNA","Primary Melanoma_017","primary_melanoma_017","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.85(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1453(follow-up time (months): 47","Homo sapiens",NA,"RNA","Primary Melanoma_018","primary_melanoma_018","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,71,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 0.72(time to 1st recurrence (days): 3497(time to 1st recurrence (months): 115(time to b-met (days): 3703(follow-up time (days): 3735(follow-up time (months): 122","Homo sapiens",NA,"RNA","Primary Melanoma_019","primary_melanoma_019","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,43,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 6(time to 1st recurrence (days): 1463(time to 1st recurrence (months): 48(time to b-met (days): NA(follow-up time (days): 5119(follow-up time (months): 168","Homo sapiens",NA,"RNA","Primary Melanoma_020","primary_melanoma_020","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,74,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 24(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 3185(follow-up time (months): 104","Homo sapiens",NA,"RNA","Primary Melanoma_021","primary_melanoma_021","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 13(time to 1st recurrence (days): 928(time to 1st recurrence (months): 30(time to b-met (days): NA(follow-up time (days): 3763(follow-up time (months): 123","Homo sapiens",NA,"RNA","Primary Melanoma_022","primary_melanoma_022","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,76,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2513(follow-up time (months): 82","Homo sapiens",NA,"RNA","Primary Melanoma_023","primary_melanoma_023","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,53,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.9(time to 1st recurrence (days): 1999(time to 1st recurrence (months): 66(time to b-met (days): NA(follow-up time (days): 5081(follow-up time (months): 166","Homo sapiens",NA,"RNA","Primary Melanoma_024","primary_melanoma_024","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,55,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 6(time to 1st recurrence (days): 201(time to 1st recurrence (months): 7(time to b-met (days): NA(follow-up time (days): 440(follow-up time (months): 14","Homo sapiens",NA,"RNA","Primary Melanoma_025","primary_melanoma_025","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,91,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.4(time to 1st recurrence (days): 532(time to 1st recurrence (months): 18(time to b-met (days): NA(follow-up time (days): 665(follow-up time (months): 21","Homo sapiens",NA,"RNA","Primary Melanoma_026","primary_melanoma_026","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,62,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.9(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2801(follow-up time (months): 92","Homo sapiens",NA,"RNA","Primary Melanoma_027","primary_melanoma_027","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 8(time to 1st recurrence (days): 56(time to 1st recurrence (months): 2(time to b-met (days): 228(follow-up time (days): 267(follow-up time (months): 8","Homo sapiens",NA,"RNA","Primary Melanoma_028","primary_melanoma_028","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,42,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 11.5(time to 1st recurrence (days): 220(time to 1st recurrence (months): 7(time to b-met (days): 220(follow-up time (days): 1740(follow-up time (months): 57","Homo sapiens",NA,"RNA","Primary Melanoma_029","primary_melanoma_029","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,28,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.7(time to 1st recurrence (days): 127(time to 1st recurrence (months): 4(time to b-met (days): 336(follow-up time (days): 368(follow-up time (months): 12","Homo sapiens",NA,"RNA","Primary Melanoma_030","primary_melanoma_030","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,52,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 6.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1949(follow-up time (months): 64","Homo sapiens",NA,"RNA","Primary Melanoma_031","primary_melanoma_031","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.48(time to 1st recurrence (days): 741(time to 1st recurrence (months): 25(time to b-met (days): 1209(follow-up time (days): 1351(follow-up time (months): 44","Homo sapiens",NA,"RNA","Primary Melanoma_032","primary_melanoma_032","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.06(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2266(follow-up time (months): 74","Homo sapiens",NA,"RNA","Primary Melanoma_033","primary_melanoma_033","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,73,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5(time to 1st recurrence (days): 477(time to 1st recurrence (months): 16(time to b-met (days): NA(follow-up time (days): 1483(follow-up time (months): 48","Homo sapiens",NA,"RNA","Primary Melanoma_034","primary_melanoma_034","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,53,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 8(time to 1st recurrence (days): 1945(time to 1st recurrence (months): 63(time to b-met (days): NA(follow-up time (days): 2546(follow-up time (months): 83","Homo sapiens",NA,"RNA","Primary Melanoma_035","primary_melanoma_035","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.87(time to 1st recurrence (days): 357(time to 1st recurrence (months): 12(time to b-met (days): NA(follow-up time (days): 363(follow-up time (months): 11","Homo sapiens",NA,"RNA","Primary Melanoma_036","primary_melanoma_036","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,62,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.12(time to 1st recurrence (days): 2006(time to 1st recurrence (months): 66(time to b-met (days): 2006(follow-up time (days): 2155(follow-up time (months): 70","Homo sapiens",NA,"RNA","Primary Melanoma_037","primary_melanoma_037","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.49(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 791(follow-up time (months): 25","Homo sapiens",NA,"RNA","Primary Melanoma_038","primary_melanoma_038","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,88,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): 553(time to 1st recurrence (months): 19(time to b-met (days): NA(follow-up time (days): 1695(follow-up time (months): 55","Homo sapiens",NA,"RNA","Primary Melanoma_039","primary_melanoma_039","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 12(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2322(follow-up time (months): 76","Homo sapiens",NA,"RNA","Primary Melanoma_040","primary_melanoma_040","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,51,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 7(time to 1st recurrence (days): 886(time to 1st recurrence (months): 29(time to b-met (days): NA(follow-up time (days): 2486(follow-up time (months): 81","Homo sapiens",NA,"RNA","Primary Melanoma_041","primary_melanoma_041","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.6(time to 1st recurrence (days): 620(time to 1st recurrence (months): 20(time to b-met (days): 826(follow-up time (days): 920(follow-up time (months): 30","Homo sapiens",NA,"RNA","Primary Melanoma_042","primary_melanoma_042","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,53,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.9(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2296(follow-up time (months): 75","Homo sapiens",NA,"RNA","Primary Melanoma_043","primary_melanoma_043","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.5(time to 1st recurrence (days): 1348(time to 1st recurrence (months): 45(time to b-met (days): NA(follow-up time (days): 2200(follow-up time (months): 72","Homo sapiens",NA,"RNA","Primary Melanoma_044","primary_melanoma_044","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.7(time to 1st recurrence (days): 408(time to 1st recurrence (months): 13(time to b-met (days): NA(follow-up time (days): 757(follow-up time (months): 24","Homo sapiens",NA,"RNA","Primary Melanoma_045","primary_melanoma_045","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,91,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.25(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1461(follow-up time (months): 48","Homo sapiens",NA,"RNA","Primary Melanoma_046","primary_melanoma_046","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.6(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1363(follow-up time (months): 44","Homo sapiens",NA,"RNA","Primary Melanoma_047","primary_melanoma_047","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,69,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): 479(time to 1st recurrence (months): 16(time to b-met (days): NA(follow-up time (days): 984(follow-up time (months): 32","Homo sapiens",NA,"RNA","Primary Melanoma_048","primary_melanoma_048","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,64,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 6(time to 1st recurrence (days): 302(time to 1st recurrence (months): 10(time to b-met (days): NA(follow-up time (days): 471(follow-up time (months): 15","Homo sapiens",NA,"RNA","Primary Melanoma_049","primary_melanoma_049","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,89,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1520(follow-up time (months): 49","Homo sapiens",NA,"RNA","Primary Melanoma_050","primary_melanoma_050","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,69,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 8(time to 1st recurrence (days): 454(time to 1st recurrence (months): 15(time to b-met (days): NA(follow-up time (days): 728(follow-up time (months): 23","Homo sapiens",NA,"RNA","Primary Melanoma_051","primary_melanoma_051","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,42,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.8(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1597(follow-up time (months): 52","Homo sapiens",NA,"RNA","Primary Melanoma_052","primary_melanoma_052","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2(time to 1st recurrence (days): 222(time to 1st recurrence (months): 8(time to b-met (days): 476(follow-up time (days): 667(follow-up time (months): 21","Homo sapiens",NA,"RNA","Primary Melanoma_053","primary_melanoma_053","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,58,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 0.85(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1995(follow-up time (months): 65","Homo sapiens",NA,"RNA","Primary Melanoma_054","primary_melanoma_054","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,67,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.85(time to 1st recurrence (days): 1841(time to 1st recurrence (months): 60(time to b-met (days): 2433(follow-up time (days): 2463(follow-up time (months): 80","Homo sapiens",NA,"RNA","Primary Melanoma_055","primary_melanoma_055","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,56,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5(time to 1st recurrence (days): 259(time to 1st recurrence (months): 8(time to b-met (days): NA(follow-up time (days): 585(follow-up time (months): 19","Homo sapiens",NA,"RNA","Primary Melanoma_056","primary_melanoma_056","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.5(time to 1st recurrence (days): 912(time to 1st recurrence (months): 30(time to b-met (days): 1006(follow-up time (days): 1163(follow-up time (months): 38","Homo sapiens",NA,"RNA","Primary Melanoma_057","primary_melanoma_057","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,52,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1756(follow-up time (months): 57","Homo sapiens",NA,"RNA","Primary Melanoma_058","primary_melanoma_058","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,78,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.4(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2108(follow-up time (months): 69","Homo sapiens",NA,"RNA","Primary Melanoma_059","primary_melanoma_059","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,56,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.1(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1026(follow-up time (months): 33","Homo sapiens",NA,"RNA","Primary Melanoma_060","primary_melanoma_060","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,76,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): 181(time to 1st recurrence (months): 6(time to b-met (days): 726(follow-up time (days): 873(follow-up time (months): 28","Homo sapiens",NA,"RNA","Primary Melanoma_061","primary_melanoma_061","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): 892(time to 1st recurrence (months): 29(time to b-met (days): 1393(follow-up time (days): 1507(follow-up time (months): 49","Homo sapiens",NA,"RNA","Primary Melanoma_062","primary_melanoma_062","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,74,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1850(follow-up time (months): 60","Homo sapiens",NA,"RNA","Primary Melanoma_063","primary_melanoma_063","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,71,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.13(time to 1st recurrence (days): 455(time to 1st recurrence (months): 15(time to b-met (days): NA(follow-up time (days): 1763(follow-up time (months): 57","Homo sapiens",NA,"RNA","Primary Melanoma_064","primary_melanoma_064","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,78,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.8(time to 1st recurrence (days): 358(time to 1st recurrence (months): 11(time to b-met (days): 762(follow-up time (days): 1259(follow-up time (months): 41","Homo sapiens",NA,"RNA","Primary Melanoma_065","primary_melanoma_065","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,53,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1090(follow-up time (months): 35","Homo sapiens",NA,"RNA","Primary Melanoma_066","primary_melanoma_066","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.85(time to 1st recurrence (days): 430(time to 1st recurrence (months): 14(time to b-met (days): NA(follow-up time (days): 1133(follow-up time (months): 37","Homo sapiens",NA,"RNA","Primary Melanoma_067","primary_melanoma_067","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,56,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.5(time to 1st recurrence (days): 710(time to 1st recurrence (months): 23(time to b-met (days): 726(follow-up time (days): 889(follow-up time (months): 29","Homo sapiens",NA,"RNA","Primary Melanoma_068","primary_melanoma_068","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.8(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 868(follow-up time (months): 28","Homo sapiens",NA,"RNA","Primary Melanoma_069","primary_melanoma_069","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,39,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1254(follow-up time (months): 41","Homo sapiens",NA,"RNA","Primary Melanoma_070","primary_melanoma_070","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,88,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1492(follow-up time (months): 49","Homo sapiens",NA,"RNA","Primary Melanoma_071","primary_melanoma_071","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,81,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 0.85(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1415(follow-up time (months): 46","Homo sapiens",NA,"RNA","Primary Melanoma_072","primary_melanoma_072","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.88(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1023(follow-up time (months): 33","Homo sapiens",NA,"RNA","Primary Melanoma_073","primary_melanoma_073","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,37,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.25(time to 1st recurrence (days): 1283(time to 1st recurrence (months): 42(time to b-met (days): NA(follow-up time (days): 1315(follow-up time (months): 43","Homo sapiens",NA,"RNA","Primary Melanoma_074","primary_melanoma_074","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,64,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 5.5(time to 1st recurrence (days): 561(time to 1st recurrence (months): 18(time to b-met (days): NA(follow-up time (days): 862(follow-up time (months): 28","Homo sapiens",NA,"RNA","Primary Melanoma_075","primary_melanoma_075","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,78,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 0.52(time to 1st recurrence (days): 2302(time to 1st recurrence (months): 75(time to b-met (days): 2319(follow-up time (days): 2817(follow-up time (months): 92","Homo sapiens",NA,"RNA","Primary Melanoma_076","primary_melanoma_076","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,66,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1668(follow-up time (months): 54","Homo sapiens",NA,"RNA","Primary Melanoma_077","primary_melanoma_077","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,78,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.2(time to 1st recurrence (days): 177(time to 1st recurrence (months): 6(time to b-met (days): NA(follow-up time (days): 345(follow-up time (months): 11","Homo sapiens",NA,"RNA","Primary Melanoma_078","primary_melanoma_078","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,61,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1708(follow-up time (months): 56","Homo sapiens",NA,"RNA","Primary Melanoma_079","primary_melanoma_079","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,56,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 10(time to 1st recurrence (days): 1086(time to 1st recurrence (months): 36(time to b-met (days): NA(follow-up time (days): 2703(follow-up time (months): 88","Homo sapiens",NA,"RNA","Primary Melanoma_080","primary_melanoma_080","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.05(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 596(follow-up time (months): 19","Homo sapiens",NA,"RNA","Primary Melanoma_081","primary_melanoma_081","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,86,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 8(time to 1st recurrence (days): 629(time to 1st recurrence (months): 20(time to b-met (days): NA(follow-up time (days): 778(follow-up time (months): 25","Homo sapiens",NA,"RNA","Primary Melanoma_082","primary_melanoma_082","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,81,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 904(follow-up time (months): 29","Homo sapiens",NA,"RNA","Primary Melanoma_083","primary_melanoma_083","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 838(follow-up time (months): 27","Homo sapiens",NA,"RNA","Primary Melanoma_084","primary_melanoma_084","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,86,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 0.89(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 836(follow-up time (months): 27","Homo sapiens",NA,"RNA","Primary Melanoma_085","primary_melanoma_085","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.25(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1518(follow-up time (months): 49","Homo sapiens",NA,"RNA","Primary Melanoma_086","primary_melanoma_086","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,44,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): 455(time to 1st recurrence (months): 15(time to b-met (days): NA(follow-up time (days): 1580(follow-up time (months): 51","Homo sapiens",NA,"RNA","Primary Melanoma_087","primary_melanoma_087","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,82,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.24(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1575(follow-up time (months): 51","Homo sapiens",NA,"RNA","Primary Melanoma_088","primary_melanoma_088","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,70,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 13(time to 1st recurrence (days): 1189(time to 1st recurrence (months): 39(time to b-met (days): 1659(follow-up time (days): 1733(follow-up time (months): 57","Homo sapiens",NA,"RNA","Primary Melanoma_089","primary_melanoma_089","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,28,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): 1530(time to 1st recurrence (months): 50(time to b-met (days): 1673(follow-up time (days): 2041(follow-up time (months): 67","Homo sapiens",NA,"RNA","Primary Melanoma_090","primary_melanoma_090","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,48,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.37(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1172(follow-up time (months): 38","Homo sapiens",NA,"RNA","Primary Melanoma_091","primary_melanoma_091","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,63,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.15(time to 1st recurrence (days): 469(time to 1st recurrence (months): 15(time to b-met (days): NA(follow-up time (days): 1519(follow-up time (months): 49","Homo sapiens",NA,"RNA","Primary Melanoma_092","primary_melanoma_092","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,66,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 8.5(time to 1st recurrence (days): 83(time to 1st recurrence (months): 2(time to b-met (days): NA(follow-up time (days): 226(follow-up time (months): 7","Homo sapiens",NA,"RNA","Primary Melanoma_093","primary_melanoma_093","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): 553(time to 1st recurrence (months): 19(time to b-met (days): NA(follow-up time (days): 1497(follow-up time (months): 49","Homo sapiens",NA,"RNA","Primary Melanoma_094","primary_melanoma_094","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,58,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.37(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 720(follow-up time (months): 23","Homo sapiens",NA,"RNA","Primary Melanoma_095","primary_melanoma_095","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 7(time to 1st recurrence (days): 3(time to 1st recurrence (months): 0(time to b-met (days): 3(follow-up time (days): 567(follow-up time (months): 18","Homo sapiens",NA,"RNA","Primary Melanoma_096","primary_melanoma_096","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,56,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.55(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1486(follow-up time (months): 48","Homo sapiens",NA,"RNA","Primary Melanoma_097","primary_melanoma_097","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,42,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1358(follow-up time (months): 44","Homo sapiens",NA,"RNA","Primary Melanoma_098","primary_melanoma_098","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,49,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): 901(time to 1st recurrence (months): 29(time to b-met (days): 1240(follow-up time (days): 1252(follow-up time (months): 41","Homo sapiens",NA,"RNA","Primary Melanoma_099","primary_melanoma_099","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,81,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.3(time to 1st recurrence (days): 588(time to 1st recurrence (months): 20(time to b-met (days): 588(follow-up time (days): 1407(follow-up time (months): 46","Homo sapiens",NA,"RNA","Primary Melanoma_100","primary_melanoma_100","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.2(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 848(follow-up time (months): 27","Homo sapiens",NA,"RNA","Primary Melanoma_101","primary_melanoma_101","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.95(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1326(follow-up time (months): 43","Homo sapiens",NA,"RNA","Primary Melanoma_102","primary_melanoma_102","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,78,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.36(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1395(follow-up time (months): 45","Homo sapiens",NA,"RNA","Primary Melanoma_103","primary_melanoma_103","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,62,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.9(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 678(follow-up time (months): 22","Homo sapiens",NA,"RNA","Primary Melanoma_104","primary_melanoma_104","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,82,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2.5(time to 1st recurrence (days): 1200(time to 1st recurrence (months): 39(time to b-met (days): NA(follow-up time (days): 1295(follow-up time (months): 42","Homo sapiens",NA,"RNA","Primary Melanoma_105","primary_melanoma_105","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,54,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2(time to 1st recurrence (days): 233(time to 1st recurrence (months): 8(time to b-met (days): 957(follow-up time (days): 1201(follow-up time (months): 39","Homo sapiens",NA,"RNA","Primary Melanoma_106","primary_melanoma_106","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,53,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 11(time to 1st recurrence (days): 148(time to 1st recurrence (months): 5(time to b-met (days): 148(follow-up time (days): 242(follow-up time (months): 7","Homo sapiens",NA,"RNA","Primary Melanoma_107","primary_melanoma_107","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,79,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4(time to 1st recurrence (days): 207(time to 1st recurrence (months): 7(time to b-met (days): NA(follow-up time (days): 374(follow-up time (months): 12","Homo sapiens",NA,"RNA","Primary Melanoma_108","primary_melanoma_108","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,91,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.2(time to 1st recurrence (days): 561(time to 1st recurrence (months): 18(time to b-met (days): NA(follow-up time (days): 1676(follow-up time (months): 55","Homo sapiens",NA,"RNA","Primary Melanoma_109","primary_melanoma_109","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,79,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 9.6(time to 1st recurrence (days): 49(time to 1st recurrence (months): 1(time to b-met (days): 152(follow-up time (days): 165(follow-up time (months): 5","Homo sapiens",NA,"RNA","Primary Melanoma_110","primary_melanoma_110","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,34,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 12(time to 1st recurrence (days): 273(time to 1st recurrence (months): 9(time to b-met (days): NA(follow-up time (days): 1570(follow-up time (months): 51","Homo sapiens",NA,"RNA","Primary Melanoma_111","primary_melanoma_111","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,62,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.62(time to 1st recurrence (days): 3965(time to 1st recurrence (months): 130(time to b-met (days): NA(follow-up time (days): 4924(follow-up time (months): 161","Homo sapiens",NA,"RNA","Primary Melanoma_112","primary_melanoma_112","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,51,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 2(time to 1st recurrence (days): 1226(time to 1st recurrence (months): 41(time to b-met (days): NA(follow-up time (days): 1623(follow-up time (months): 53","Homo sapiens",NA,"RNA","Primary Melanoma_113","primary_melanoma_113","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,44,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 4.5(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 1469(follow-up time (months): 48","Homo sapiens",NA,"RNA","Primary Melanoma_114","primary_melanoma_114","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 7(time to 1st recurrence (days): 364(time to 1st recurrence (months): 12(time to b-met (days): 544(follow-up time (days): 592(follow-up time (months): 19","Homo sapiens",NA,"RNA","Primary Melanoma_115","primary_melanoma_115","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.7(time to 1st recurrence (days): 455(time to 1st recurrence (months): 15(time to b-met (days): 455(follow-up time (days): 620(follow-up time (months): 20","Homo sapiens",NA,"RNA","Primary Melanoma_116","primary_melanoma_116","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,76,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 1.3(time to 1st recurrence (days): 352(time to 1st recurrence (months): 12(time to b-met (days): 433(follow-up time (days): 484(follow-up time (months): 15","Homo sapiens",NA,"RNA","Primary Melanoma_117","primary_melanoma_117","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,57,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3(time to 1st recurrence (days): 1879(time to 1st recurrence (months): 61(time to b-met (days): NA(follow-up time (days): 2126(follow-up time (months): 69","Homo sapiens",NA,"RNA","Primary Melanoma_118","primary_melanoma_118","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,72,NA,NA,NA,NA,NA,NA,NA,NA
"total RNA","total RNA","Cutaneous primary melanoma","Public on Feb 01 2015",NA,NA,NA,NA,"300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.","Common Reference",NA,"material: Equal mixture of all samples","300 ng total RNA from sample and reference was labelled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon, Denmark) following the procedure described by the manufacturer.",NA,"GSE62371, GSE62372",NA,"1_Exiqon is Cy3","primary tumor thickness (mm): 3.75(time to 1st recurrence (days): NA(time to 1st recurrence (months): NA(time to b-met (days): NA(follow-up time (days): 2870(follow-up time (months): 94","Homo sapiens",NA,"RNA","Primary Melanoma_119","primary_melanoma_119","The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY™ LNA microRNA array (6th gen - hsa, mmu & rno) (Exiqon, Denmark), which contains capture probes targeting all miRNAs for human, mouse or rat registered in the miRBASE version 16.0 at the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization the microarray slides w ...","Cy5 (Hy5)",NA,NA,NA,NA,NA,NA,NA,NA,47,NA,NA,NA,NA,NA,NA,NA,NA
